Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul;13(7):102482.
doi: 10.1016/j.jchf.2025.02.028. Epub 2025 Jun 3.

Vasoplegia Syndrome After Cardiac Surgery: Insights Into Mechanisms and Treatment

Affiliations
Review

Vasoplegia Syndrome After Cardiac Surgery: Insights Into Mechanisms and Treatment

Francesco Castagna et al. JACC Heart Fail. 2025 Jul.

Abstract

Vasoplegia syndrome is a specific form of vasodilatory shock encountered in patients who undergo cardiac surgery, most commonly with cardiopulmonary bypass, which is characterized by severe hypotension in the presence of normal or increased cardiac output with abnormal tissue perfusion. Although numerous risk factors have been identified, the pathophysiology remains incompletely understood, and the therapeutic strategies are limited with a consequent poor prognosis. Current research on mechanisms and treatment has focused on targeting disequilibrium in the biological mediators of vasodilation and vasoconstriction that leads to profound hypotension and end-organ malperfusion. The morbidity and mortality rates are high, making vasoplegia syndrome a clinical area of unmet need. Looking ahead, use of standardized definitions and reporting of prospective outcomes as well as investigations into new mechanisms will be critical to identifying novel therapeutic targets and reducing the burden of vasoplegia syndrome.

Keywords: cardiac surgery; cardiopulmonary bypass; hypotension; shock; vasoplegia syndrome.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures Dr Mehra has received consulting fees from Abbott and Cadrenal (paid to his institution for clinical trial leadership), Natera, Paragonix, Moderna, NuPulseCV, FineHeart, TransMedics, Leviticus Cardio, FIRE1, and Second Heart Assist (uncompensated). Dr Nabzdyk has equity ownership and roles as co-founder and chair of the scientific advisory board of SanaHeal (Equity); and has received clinical research funding from Abiomed. Dr Givertz has received scientific advisory board fees from Merck and Aera Therapeutics, and research funding from Natera, Abbott, Endotronix, and the National Heart, Lung, and Blood Institute. Dr Castagna has reported that he has no relationships relevant to the contents of this paper to disclose.

MeSH terms

LinkOut - more resources